Honasa buys 58% of Fluence Pharma at ₹135 cr, pushes Mamaearth parent into nutraceuticals
The Mamaearth and The Derma Co owner is acquiring a controlling 58% stake in nutraceutical firm Fluence Pharma at a ₹135 crore enterprise valuation, marking Honasa's first material step beyond beauty and personal care into ingestible wellness — a category adjacency rivals like Nykaa and HUL are also chasing.
Honasa Consumer, parent of Mamaearth and The Derma Co, will acquire a 58% stake in nutraceutical firm Fluence Pharma at an enterprise valuation of ₹135 crore, extending its beauty and personal care portfolio into wellness.